Combining high-throughput pharmacokinetic screens at the hits-to-leads stage of drug discovery.
Profound technological advances in the drug discovery process have led to the identification of an increasingly large number of promising compounds at the hits-to-leads stage. Higher-throughput pharmacokinetic screens have therefore been developed to enhance the tractability of selected leads and minimize the risk of failure in the later stages of drug development.
Spalding
D J.M.
DJ
BioMet Discovery 1 BioMet Division GlaxoWellcome R&D Park Road, SG12 0DP, Ware Herts, UK
Harker
A J.
AJ
Bayliss
M K.
MK